Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03618992 · ClinicalTrials.gov registry record · NA

Improving the Appearance of Skin and Hair in Patients Undergoing Valley Fever Treatment

A NA study, sponsored by University of Arizona.

Terminated
Registry status
NA
Development phase
14
Enrollment target

NCT03618992: Clinical Trial NA study, sponsored by University of Arizona.

NCT03618992 is a NA study that was terminated before completion, run by University of Arizona. The registered enrollment target is 14 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03618992, a NA study, was terminated before completion, sponsored by University of Arizona.

TERMINATED
Registry status
NA
Development phase
14 participants
Enrollment target

Study Summary

This will be a multi-visit study that will take approximately 3 hours in total. Up to 200 subjects from the BUMC Valley Fever and BUMC Dermatology clinics will be enrolled in this study and assigned to one of three cohorts according to timeline of oral anti-fungal therapy. Subjects in Cohort 1 will be randomized to apply topical cholesterol-containing moisturizers to the skin, hair and lips on either the right or left side of the body daily. Measurements of skin barrier function, appearance of skin and hair, and hair samples will be obtained at baseline and at 4 week follow-up visits. Cohorts 2 and 3 will be observational groups at differing points in oral antifungal treatment regimen. Subjects will be randomized to have measurements of skin barrier function and hair and skin characteristics obtained from either the right or left side of the body at baseline and at monthly follow-up visits.

Primary Outcome

Assess skin barrier function through measurement of transepidermal water loss (in g/m\^2h) using a commercially-available, non-invasive device.

Interventions

  • OTHER Cholesterol-containing moisturizers

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2018-08-01
Est. Completion 2020-05-31
Phase NA
University of Arizona

349 total trials

Why NCT03618992 stopped before completion

NCT03618992 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 1 intervention - of which Cholesterol-containing moisturizers is the first listed.

NCT03618992 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03618992 about?

NCT03618992 is a clinical study titled "Improving the Appearance of Skin and Hair in Patients Undergoing Valley Fever Treatment". This will be a multi-visit study that will take approximately 3 hours in total. Up to 200 subjects from the BUMC Valley Fever and BUMC Dermatology clinics will be enrolled in this study and assigned to one of three cohorts according to timeline of oral anti-fungal therapy. Subjects in Cohort 1 will ...

What is the current status of trial NCT03618992?

This trial is currently terminated. It is a NA study. The enrollment target is 14 participants. The study started on 2018-08-01. Estimated completion is 2020-05-31.

What interventions are being tested in trial NCT03618992?

The interventions under investigation include: Cholesterol-containing moisturizers (OTHER).

Who is sponsoring clinical trial NCT03618992?

This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03618992's enrollment target sits among peer trials

14 1909th of 2000 higher than 90 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523092 · 14 participants · Phase 4

    Use of CXCL9 as a Biomarker of Acthar Efficacy

  • NCT04263285 · 14 participants · NA

    Treatment of Depression Post-SCI

  • NCT04743271 · 14 participants · NA

    Food and Circadian Timing

  • NCT05065671 · 14 participants · Phase 1

    Microbiome Derived Metabolism and Pharmacokinetics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

Source: ClinicalTrials.gov NCT03618992, the US trial registry maintained by the National Library of Medicine. NCT03618992 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.